NCT06960577 2026-02-23Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)AstraZenecaPhase 3 Recruiting150 enrolled
NCT05137262 2026-02-18A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderM.D. Anderson Cancer CenterPhase 2 Active not recruiting12 enrolled